Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q2 2024 · 10-Q
Revenue$145.28M$145.28M+7.2% vs Q2 2023 Net Income$19.61M$19.61M+50.7% vs Q2 2023 EPS Diluted$0.52$0.52+52.9% vs Q2 2023 Gross Profit$90,806,000+23.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$67,398,000−32.4% Free Cash Flowderived$67,128,000−32.6% Margins · derivedGross margin62.5%+8.0 pt vs Q2 2023
Operating margin32.7%+6.4 pt vs Q2 2023
Net margin13.5%+3.9 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 8, 2024 · 39 d after period end